

Open camera or QR reader and scan code to access this article and other resources online.



## Bcl11b and Atoh8 Coordinate Cellular Plasticity for Reprogramming and Transformation

Mo-Fan Huang,<sup>1,2</sup> Rachel Shoemaker,<sup>1,3</sup> and Dung-Fang Lee<sup>1,2,4,5</sup>

### Abstract

By dissecting and comparing the transcriptional trajectories and epigenomic traits of reprogramming and transforming cells at the single-cell resolution, Huyghe et al discovered Bcl11b and Atoh8, two key transcription factors controlling cell plasticity during pluripotent reprogramming and oncogenic transformation.

**Keywords:** cellular plasticity, reprogramming, transformation, single-cell

**D**URING DEVELOPMENT, EMBRYOS PROGRESSIVELY DIFFERENTIATE into functionally and phenotypically distinct cells to form multicellular organisms. This irreversible developmental process generates unique cellular identities with cell type-specific gene expression programs throughout the human lifespan. Stable fixed cellular plasticity and identification can be largely amended by pluripotent reprogramming (Takahashi and Yamanaka, 2006), direct reprogramming (Wang et al, 2021), and oncogenic transformation (Puisieux et al, 2018).

The high similarity between pluripotent reprogramming and oncogenic transformation is evident by their likeness in common biological processes [e.g., glycolytic metabolism (Warburg, 1956; Warburg et al, 1927)], transcription factors [e.g., c-Myc (Land et al, 1986, Land et al, 1983; Takahashi and Yamanaka, 2006), and p53 (Lee et al, 2015, Lee et al, 2012)], epigenetic modifiers [e.g., MLL1/WDR5 complex (Ang et al (2011))], etc. However, the molecular mechanisms involved in loss of original cell identity and reshaping through cellular plasticity during the early stages of reprogramming and transformation remain nebulous.

To understand the coordinated changes of cellular plasticity and identity that are critical for both reprogramming and transformation, a new study led by Huyghe et al (2022) dissected the comparative single-cell trajectories of pluripotent reprogramming (through Oct4, Sox2, Klf4, and c-Myc [OSKM]) (Takahashi and Yamanaka, 2006) and oncogenic transformation (through K-ras<sup>G12D</sup> and c-Myc) (Ischenko et al, 2013; Land et al, 1986, Land et al, 1983) (Fig. 1). The authors utilized powerful reprotransformable mice with conditionally doxycycline-induced OSKM expression or tamoxifen-induced K-ras<sup>G12D</sup> expression, combined with c-Myc overexpression, in the same population of somatic cells.

They conducted single-cell RNA sequencing to measure RNA expression in mouse embryonic fibroblasts (MEFs) after both 5 days and 10 days of OSKM or K-ras<sup>G12D</sup>/c-Myc overexpression, as well as in fully reprogrammed induced pluripotent stem cells (iPSCs) and transformed cells. In addition, they performed principal component analysis and *t*-distributed stochastic neighbor embedding to define 12 clusters among 30,146 single cells and then utilized diffusion maps and slingshot to rebuild the pseudotemporal


<sup>1</sup>Department of Integrative Biology and Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas, USA.

<sup>2</sup>UTHealth Houston Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

<sup>3</sup>Department of Biosciences, Weiss School of Natural Sciences, Rice University, Houston, Texas, USA.

<sup>4</sup>School of Biomedical Informatics, Center for Precision Health, The University of Texas Health Science Center at Houston, Houston, Texas, USA.

<sup>5</sup>Center for Stem Cell and Regenerative Medicine, The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, The University of Texas Health Science Center at Houston, Houston, Texas, USA.



**FIG. 1.** Schematic recapitulating this study to identify key regulators during the multistep processes of cell pluripotent reprogramming and oncogenic transformation through single-cell sequencing techniques. Loss of somatic cell identity and gain of cell plasticity can be induced from reprotransformable mice MEFs. Bcl11b and Thy1 serve as markers to distinguish cellular intermediates that tend to develop pluripotent cells or cancer cells during cell fate transitions. The transcription factor Atoh8 restrains the emergence of cell plasticity by transcriptional regulation of Wnt signaling activity and c-Myc self-antagonization. The figure is created using (BioRender.com). MEFs, mouse embryonic fibroblasts; Atoh8, atonal bHLH transcription factor 8.

progression during pluripotent reprogramming and oncogenic transformation. Their designed single-cell trajectories allowed them to transiently identify the intersection of specific clusters of cells before the diversion of pluripotent reprogramming and oncogenic transformation.

By computing the marker genes predominantly found in MEFs, they selected the glycoprotein Thy1 (Polo et al, 2012), a known MEF marker during pluripotent reprogramming, and the transcriptional factor (TF) Bcl11b (Li et al, 2010; Wakabayashi et al, 2003), a hematopoiesis-associated TF that is downregulated during reprogramming and transformation and silenced in iPSCs and transformed cells, as a marker for further investigation. In comparison with other cell populations, they found that cells with Bcl11b<sup>low</sup> Thy1<sup>low</sup> acquired the cellular plasticity tendency to form pluripotent stem cells or aggressive tumors.

Suppression of Bcl11b and/or Thy1 facilitated MEF reprogramming to pluripotency and transformation to malignancy. Interestingly, Bcl11b<sup>low</sup> Thy1<sup>low</sup> cells still maintained their original cellular identities, suggesting a disengaged process of gain of new plasticity and loss of original identity during pluripotent reprogramming and oncogenic transformation.

They then comprehensively characterized the molecular signatures of reprogramming and transformation using Bcl11b<sup>low</sup> Thy1<sup>low</sup> intermediate cells and unveiled that atonal bHLH transcription factor 8 (Atoh8) is a negative regulator of cell plasticity and is downregulated during re-

programming and transformation. Depletion of Atoh8 enhances OSKM-induced reprogramming and Kras<sup>G12D</sup>/c-Myc-induced transformation. Mechanistically, inhibition of Atoh8 leads to the emergence of the Bcl11b<sup>low</sup> Thy1<sup>low</sup> cell population through activation of the Wnt pathway through Sfrp1 suppression and c-Myc upregulation, which are two critical signaling regulators for tissue regeneration and tumor formation.

Moreover, Atoh8 preferentially occupies inaccessible regions (ATAC-seq-positive) of enhancers and binds with Bcl11b on the Atoh8 locus for activation, whereas the binding of Atoh8-bound regions by c-Myc is finely switched from somatic cells (Atoh8<sup>high</sup>c-Myc<sup>low</sup>) to iPSCs and/or transformed cells (Atoh8<sup>low</sup>c-Myc<sup>high</sup>), indicating relocation of c-Myc during reprogramming and/or transformation.

In summary, the study by Huyghe et al (2022) discovered key regulators controlling cell plasticity during pluripotent reprogramming and oncogenic transformation by dissecting and comparing the transcriptional trajectories of reprogramming and transforming cells. Their findings provide a new insight into how TF-mediated regulatory networks fine-tune cellular plasticity during pluripotent reprogramming and oncogenic transformation.

#### Authors' Contributions

M.-F.H., R.S., and D.-F.L. wrote the article. M.-F.H. made the figure.

### Author Disclosure Statement

The authors declare they have no conflicting financial interests.

### Funding Information

D.-F.L. was supported by CPRIT RR160019 and NIH/NCI R01CA246130. D.-F.L. is a CPRIT scholar in cancer research.

### References

- Ang YS, Tsai SY, Lee DF, et al. Wdr5 mediates self-renewal and reprogramming through the embryonic stem cell core transcriptional network. *Cell* 2011;145(2):183–197; doi: 10.1016/j.cell.2011.03.003
- Huyghe A, Furlan G, Schroeder J, et al. Comparative roadmaps of reprogramming and oncogenic transformation identify Bcl11b and Atoh8 as broad regulators of cellular plasticity. *Nat Cell Biol* 2022;24(9):1350–1363; doi: 10.1038/s41556-022-00986-w
- Ischenko I, Zhi J, Moll UM, et al. Direct reprogramming by oncogenic Ras and Myc. *Proc Natl Acad Sci U S A* 2013;110(10):3937–3942; doi: 10.1073/pnas.1219592110
- Land H, Chen AC, Morgenstern JP, et al. Behavior of myc and ras oncogenes in transformation of rat embryo fibroblasts. *Mol Cell Biol* 1986;6(6):1917–1925; doi: 10.1128/mcb.6.6.1917–1925.1986
- Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. *Nature* 1983;304(5927):596–602; doi: 10.1038/304596a0
- Lee DF, Su J, Ang YS, et al. Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling. *Cell Stem Cell* 2012;11(2):179–194; doi: 10.1016/j.stem.2012.05.020
- Lee DF, Su J, Kim HS, et al. Modeling familial cancer with induced pluripotent stem cells. *Cell* 2015;161(2):240–254; doi: 10.1016/j.cell.2015.02.045
- Li P, Burke S, Wang J, et al. Reprogramming of T cells to natural killer-like cells upon Bcl11b deletion. *Science* 2010;329(5987):85–89; doi: 10.1126/science.1188063
- Polo JM, Anderssen E, Walsh RM, et al. A molecular roadmap of reprogramming somatic cells into iPS cells. *Cell* 2012;151(7):1617–1632; doi: 10.1016/j.cell.2012.11.039
- Puisieux A, Pommier RM, Morel AP, et al. Cellular pliancy and the multistep process of tumorigenesis. *Cancer Cell* 2018;33(2):164–172; doi: 10.1016/j.ccell.2018.01.007
- Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 2006;126(4):663–676; doi: 10.1016/j.cell.2006.07.024
- Wakabayashi Y, Watanabe H, Inoue J, et al. Bcl11b is required for differentiation and survival of alphabeta T lymphocytes. *Nat Immunol* 2003;4(6):533–539; doi: 10.1038/ni927
- Wang H, Yang Y, Liu J, et al. Direct cell reprogramming: Approaches, mechanisms and progress. *Nat Rev Mol Cell Biol* 2021;22(6):410–424; doi: 10.1038/s41580-021-00335-z
- Warburg O. On the origin of cancer cells. *Science* 1956;123(3191):309–314; doi: 10.1126/science.123.3191.309.
- Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. *J Gen Physiol* 1927;8(6):519–530; doi: 10.1085/jgp.8.6.519

Address correspondence to:

*Dung-Fang Lee*  
*Department of Integrative Biology and Pharmacology*  
*McGovern Medical School*  
*The University of Texas Health Science Center*  
*at Houston*  
*Houston, TX 77030*  
*USA*

*E-mail: dung-fang.lee@uth.tmc.edu*